TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3567466
Drug: CT with
Normalized name: Impact with Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT with 16.25 g iodine contrast medium
Study: 3567466
Drug: CT with
Normalized name: Impact with Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT with 32.5 g iodine contrast medium
Study: 3567466
Drug: CT without
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT without intravenous contrast medium
Study: 29798249
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous analgesia (Group A)
Study: 29798249
Drug: Ibuprofen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (5 mg/kg/sub) (Group B)
Study: 21908460
Drug: Abrupt quitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt quitting with nicotine lozenge, quit date set between 1 and 3 weeks after study onset.
Study: 21908460
Drug: Gradual quitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual quitting with nicotine lozenge, quit date set between 3 and 5 weeks after study entry.
Study: 16488057
Drug: 2‐L pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐L pulse lavage normal saline washout
Study: 16488057
Drug: 2‐L normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐L normal saline washout via a jug or a syringe
Study: 8856712
Drug: Adenosine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (low dose)
Study: 8856712
Drug: Adenosine (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (increasing doses)
Study: 6094373
Drug: NaHCO3 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.2 g/kg B.W.)
Study: 27049826
Drug: Hydromorphone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (up to 3 times daily for 6 months)
Study: 27049826
Drug: Diacetylmorphine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetylmorphine (up to 3 times daily for 6 months)
Study: 25057155
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with water
Study: 25057155
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with food
Study: 25057155
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg Fe with food
Study: 25057155
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe without food
Study: 22192729
Drug: Intravenous aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous aflibercept (4 mg/kg every 2 weeks)
Study: 24127346
Drug: Intravenous aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous aflibercept
Study: 17097649
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate 50 mg/m(2) administered on days 0 and 4; additional doses on day 7 and/or day 11 if hCG levels did not decrease by 15%
Study: 16199417
Drug: Single-injection thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection thoracic paravertebral block with bupivacaine 0.375% and adrenaline 1:200 000 0.4 ml kg(‐1) plus i.v. patient‐controlled analgesia (PCA) with morphine
Study: 16199417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with back puncture without injection and morphine PCA
Study: 7478700
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral tramadol
Study: 7478700
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol + 60 mg codeine (active control)
Study: 1545135
Drug: Sphingosines (D-sphingosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sphingosines (D-sphingosine, D,L-sphinganine, 4-D-hydroxysphinganine, oleoyl-sphingosine, N,N-dimethylsphingosine)
Study: 29119559
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous methylprednisolone (MP) 125 mg
Study: 23828016
Drug: Ultrasound-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection
Study: 23828016
Drug: Palpation-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided intra-articular injection
Study: 20489027
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Study: 20489027
Drug: darunavir/ritonavir 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 600/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Study: 20489027
Drug: S/GSK1349572 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 30 mg once daily
Study: 15095653
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of all cardiovascular risk factors
Study: 11342895
Drug: Oxybutynin 2.5
Normalized name: oxyBUTYnin 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 2.5 mg twice daily (increased to 5 mg after 2 weeks)
Study: 1539476
Drug: Propofol anaesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anaesthesia (Group G)
Study: 1539476
Drug: p-deletion score
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-deletion score (Group G)
Study: 3886311
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with penicillin/pivampicillin
Study: 30995174
Drug: Pelvic Radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic Radiation Therapy (RT) at 45 to 50.4 Gy over 5 weeks
Study: 26045170
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg • kg(-1) anhydrous caffeine)
Study: 25440232
Drug: Bone injection
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone injection gun (BIG)
Study: 10075337
Drug: Oral biotin
Normalized name: biotin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral biotin (2.1 micromol)
Study: 10075337
Drug: Oral biotin
Normalized name: biotin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral biotin (8.2 micromol)
Study: 10075337
Drug: Oral biotin
Normalized name: biotin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral biotin (81.9 micromol)
Study: 10075337
Drug: Intravenous biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous biotin (18.4 micromol)
Study: 10075337
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of biotin (oral and intravenous)
Study: 10075337
Drug: Intravenous biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous biotin and largest oral dose
Study: 434682
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug regimen (beta-lactam antibiotic)
Study: 434682
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic regimen (beta-lactam antibiotic + aminoglycoside)
Study: 21857273
Drug: Single-injection sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection sciatic nerve block (Fs group)
Study: 18718986
Drug: Etanercept added
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept added to methotrexate monotherapy
Study: 18718986
Drug: Methotrexate added
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate added to etanercept monotherapy
Study: 18718986
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (etanercept + methotrexate)
Study: 28196046
Drug: Test (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test (new oral formulation of levosulpiride, tablet 25 mg)
Study: 28196046
Drug: Reference (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (commercially available formulation, tablet 25 mg)
Study: 25355797
Drug: Nonadjuvanted whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine (doses ranging from 3.75 to 45 μg of hemagglutinin antigen)
Study: 25355797
Drug: Nonadjuvanted whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine
Study: 24292351
Drug: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol) intake of 2.46 g/day for 7 days
Study: 10480191
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of cerivastatin sodium once daily
Study: 10480191
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg of cerivastatin sodium once daily
Study: 10480191
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results of 0.3 mg and 0.15 mg groups
Study: 8620266
Drug: Computer-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted treatment planner
Study: 8620266
Drug: Interactive patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive patient education/therapy
Study: 26520401
Drug: Parenteral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily (ARTES)
Study: 26520401
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of quinine base at 16.6 mg/kg followed by maintenance dose of 8.3 mg/kg (QLD)
Study: 26520401
Drug: 8.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.3 mg/kg quinine base every 8 hours (QNLD3)
Study: 26520401
Drug: 12.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/kg quinine base every 12 hours (QNLD2)
Study: 22021142
Drug: PHILOS augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHILOS augmentation plus minimally invasive injectable graft (MIIG) X3 Hivisc (Group B)
Study: 18723296
Drug: Concurrent cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin-based chemotherapy (Group 3)
Study: 18723296
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and concurrent chemotherapy
Study: 18723296
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the cochlea
Study: 16925684
Drug: Allergoid immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergoid immunotherapy
Study: 11322745
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose at treatment endpoint = 0.05 mg/kg; mean total dose = 1.2 mg/day)
Study: 9165504
Drug: High-dose toremifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose toremifene (200 or 240 mg/d)
Study: 9165504
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 or 40 mg/d)
Study: 8427853
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment groups
Study: 29787858
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation counseling plus nicotine replacement therapy (C + NRT)
Study: 22895351
Drug: 4 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg/d propranolol for 12 months postburn
Study: 17910332
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with Culex quinquefasciatus extract
Study: 11574763
Drug: Mito-FLAG protocol
Normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-FLAG protocol (mitoxantrone 7 mg/m² days 1/3/5, fludarabine 15 mg/m² every 12 h days 1-5, cytarabine as bolus infusion 1000 mg/m² over 1 h every 12 h days 1-5)
Study: 11574763
Drug: Mito-FLAG protocol
Normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-FLAG protocol (cytarabine as continuous infusion 100-150 mg/m² over 24 h days 1-5)
Study: 9692704
Drug: 1-hour topical
Normalized name: 3α-(diphenylmethoxy)-1αH,5αH-tropane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour topical method (bismuth, metronidazole, amoxycillin, pronase) after a 6-week course of ranitidine and omeprazole
Study: 9692704
Drug: Amoxycillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (2 g/day) plus omeprazole (20 mg b.d.) for 2 weeks followed by a 4-week course of ranitidine
Study: 7933682
Drug: ATP infusion
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP infusion at 0.16 mg/kg/min (group A)
Study: 7933682
Drug: ATP infusion
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP infusion at 0.18 mg/kg/min (group B)
Study: 7933682
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects from ATP infusion
Study: 24679061
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg per day)
Study: 22642525
Drug: Transdiagnostic cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive‐behavioral treatment (Unified Protocol for the Treatment of Emotional Disorders in Youth)
Study: 19295325
Drug: ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (10 mg)
Study: 18072016
Drug: simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (40 mg)
Study: 16579717
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for insomnia
Study: 15598784
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 mug/kg weekly for 4 weeks
Study: 9270645
Drug: Minimal-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minimal-dose aprotinin (1.0 x 10(6) KIU)
Study: 9270645
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2.7 +/- 0.5 x 10(6) KIU)
Study: 9270645
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aprotinin treatment)
Study: 3130221
Drug: NORPLANT-2 implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NORPLANT-2 implants
Study: 3130221
Drug: Both NORPLANT
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both NORPLANT and NORPLANT-2 implants
Study: 16644323
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels < 100 pg/mL
Study: 16644323
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels >= 100 pg/mL
Study: 12475575
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (0.4‐0.8 mg/h)
Study: 12475575
Drug: Intravenous fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoterol (60 ‐ 120 microg/h)
Study: 10849527
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (CT) - Cycle 1: cytarabine 200 mg/m2/day (days 1-7) and idarubicin 12 mg/m2/day (days 1-2)
Study: 10849527
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (CT) - Cycle 2: cytarabine 2000 mg/m2/day (days 1-6) and amsacrine 120 mg/m2/day (days 1-3)
Study: 8473644
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin for > or = 10 days and no heparin (n = 12)
Study: 8473644
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin for > or = 10 days but heparin, 10,000 IU, at the time of catheterization (n = 5)
Study: 8473644
Drug: Aspirin, 300
Normalized name: Aspirin, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 300 mg/day, for at least 5 days (n = 11)
Study: 8473644
Drug: Aspirin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 75 mg/day for > or = 5 days before angioplasty (n = 11)
Study: 8473644
Drug: Aspirin, 300
Normalized name: Aspirin, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 300 mg/day for > or = 3 days before angioplasty (n = 9)
Study: 8473644
Drug: Aspirin, 300
Normalized name: Aspirin, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 300 mg/day for > or = 3 days before angioplasty followed by 1,000 mg during angioplasty (n = 9)
Study: 2951806
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms
Study: 31663831
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous thrombolysis plus mechanical thrombectomy (MT)
Study: 31847977
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: papain 2% or 4% topical therapy, Unna boot compression therapy in phase 2
Study: 31847977
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2% hydrogel topical therapy, cellulose membrane followed by Unna boot compression therapy in phase 2
Study: 31847977
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received single-layer elastic compression therapy (SurePress; ConvaTec) and educational activities, exercises, leg elevation, oral nutrition supplementation, and ulcer cleaning
Study: 25515123
Drug: Bilateral cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral cochlear implants (CI)
Study: 11502917
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 28 days, then 10 mg/day thereafter)
Study: 9745423
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (starting dose, 10 +/- 0.3 micrograms/kg per day; mean treatment dose, 4 +/- 2 micrograms/kg per day)
Study: 28619989
Drug: Alteplase (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (both doses)
Study: 28073779
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (2 pmol·kg‐1·min‐1)
Study: 21079955
Drug: Topical cyanoacrylate
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyanoacrylate applied every 3 to 5 days for 3 months
Study: 2313465
Drug: ELISA test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA test with monoclonal antibodies against E. histolytica antigen
Study: 29339527
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone every 2 weeks for 22 weeks
Study: 26901417
Drug: Geriatric liaison
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric liaison intervention (preoperative consultation, individual treatment plan, daily visits by a geriatric nurse)
Study: 20622670
Drug: Riboflavin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 0.1% eyedrops for 1 month of topical use
Study: 15936175
Drug: Lamotrigine (LTG),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (LTG), mean daily dose of 250 mg
Study: 15936175
Drug: Sodium Valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Valproate (VPA), mean daily dose of 2070 mg
Study: 20180356
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg once daily
Study: 9501262
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl anesthesia (50 microg/kg with diazepam 0.1 mg/kg for induction, maintained with fentanyl 2 microg/kg/hr and diazepam 0.05 mg/kg/hr)
Study: 9501262
Drug: Thiopentone anesthesia
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone anesthesia (7 mg/kg for induction, maintained with enflurane 0.7‐1.5% and thiopentone 3 mg/kg/hr during CPB)
Study: 8580271
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s., Metronidazole 400 mg t.d.s. for 14 days
Study: 8580271
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s. and placebo for 14 days
Study: 29266180
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.4% dexamethasone added to 18 ml 0.5% bupivacaine‐epinephrine
Study: 29266180
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 0.9% normal saline added to 18 ml 0.5% bupivacaine‐epinephrine
Study: 23043368
Drug: CNTO 5825
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 5825 (0.1, 0.3, 1.0, 3.0, or 10 mg kg(‐1) i.v. or 3.0 mg kg(‐1) s.c.)